» Articles » PMID: 31811195

Murine Xenograft Bioreactors for Human Immunopeptidome Discovery

Overview
Journal Sci Rep
Specialty Science
Date 2019 Dec 8
PMID 31811195
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The study of peptides presented by MHC class I and class II molecules is limited by the need for relatively large cell numbers, especially when studying post-translationally modified or otherwise rare peptide species. To overcome this problem, we pose the hypothesis that human cells grown as xenografts in immunodeficient mice should produce equivalent immunopeptidomes as cultured cells. Comparing human cell lines grown either in vitro or as murine xenografts, we show that the immunopeptidome is substantially preserved. Numerous features are shared across both sample types, including peptides and proteins featured, length distributions, and HLA-binding motifs. Peptides well-represented in both groups were from more abundant proteins, or those with stronger predicted HLA binding affinities. Samples grown in vivo also recapitulated a similar phospho-immunopeptidome, with common sequences being those found at high copy number on the cell surface. These data indicate that xenografts are indeed a viable methodology for the production of cells for immunopeptidomic discovery.

Citing Articles

Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation.

Zhang W, Sun S, Zhu W, Meng D, Hu W, Yang S Int J Mol Sci. 2024; 25(7).

PMID: 38612472 PMC: 11011986. DOI: 10.3390/ijms25073660.


Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery.

Stutzmann C, Peng J, Wu Z, Savoie C, Sirois I, Thibault P Cell Rep Methods. 2023; 3(6):100511.

PMID: 37426761 PMC: 10326451. DOI: 10.1016/j.crmeth.2023.100511.


PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.

Feola S, Haapala M, Peltonen K, Capasso C, Martins B, Antignani G ACS Nano. 2021; 15(10):15992-16010.

PMID: 34605646 PMC: 8552492. DOI: 10.1021/acsnano.1c04371.


MHC Phosphopeptides: Promising Targets for Immunotherapy of Cancer and Other Chronic Diseases.

Mahoney K, Shabanowitz J, Hunt D Mol Cell Proteomics. 2021; 20:100112.

PMID: 34129940 PMC: 8724925. DOI: 10.1016/j.mcpro.2021.100112.


Establishment of a Macrophage Phenotypic Switch Related Prognostic Signature in Patients With Pancreatic Cancer.

Li M, Wang H, Yuan C, Ma Z, Jiang B, Li L Front Oncol. 2021; 11:619517.

PMID: 33747931 PMC: 7966706. DOI: 10.3389/fonc.2021.619517.


References
1.
Andreatta M, Alvarez B, Nielsen M . GibbsCluster: unsupervised clustering and alignment of peptide sequences. Nucleic Acids Res. 2017; 45(W1):W458-W463. PMC: 5570237. DOI: 10.1093/nar/gkx248. View

2.
NICHOLS E, Krakauer T, Hansen T . Two-dimensional gel comparisons of murine H-2D region-associated antigens of different H-2 haplotypes. J Immunol. 1983; 131(5):2440-4. View

3.
Bray N, Pimentel H, Melsted P, Pachter L . Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016; 34(5):525-7. DOI: 10.1038/nbt.3519. View

4.
Hornbeck P, Kornhauser J, Tkachev S, Zhang B, Skrzypek E, Murray B . PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 2011; 40(Database issue):D261-70. PMC: 3245126. DOI: 10.1093/nar/gkr1122. View

5.
Tentler J, Tan A, Weekes C, Jimeno A, Leong S, Pitts T . Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338-50. PMC: 3928688. DOI: 10.1038/nrclinonc.2012.61. View